Table 2 |
||
|
Recommendations for problem areas in antinuclear antibody kit use and application |
||
| Principal |
Problem |
Recommendations |
|
|
||
| Manufacturer |
Variable reagents and analytes |
Standardized or common sources of reagents and analytes |
| Variable secondary antibodies |
Standardized or common sources of secondary antibodies |
|
| Premarketing, beta testing and selling kits |
Wider testing in clinical laboratories before marketing and selling |
|
| Quality control and postmarketing surveillance |
Willingness and ability to adjust and to improve kit performance |
|
| Clinical laboratory |
Equipment |
Upgrading and use of equipment to standards |
| Protocols and standard operating procedures |
Follow manufacturer's protocols |
|
| Utilize international reference sera |
||
| Utilize local sera from clinically defined and normal controls to assess performance
of kit before adopting into practice |
||
| Training and maintenance of competence |
Technologist required to demonstrate competence and to participate in appropriate
educational forums |
|
| Test requisitions and reports |
Should be clear and concise |
|
| Provide clear algorithm of tests provided and approach to use (Fig. 2) |
||
| Design and adopt a universal format |
||
| Report graded positive results when appropriate or give clinically meaningful cutoff |
||
| Physician liaison |
Staff with specific skills serve as primary physician liaison to provide advice and
to assist with test interpretation |
|
| Physician |
Ordering tests |
Aware of clinical laboratory capabilities |
| Utilize graded approach to ordering tests (Figure 2) |
||
| Receiving tests |
In cooperation with ethics boards, move to digital or electronic receipt of test results
while maintaining patient confidentiality |
|
| Interpreting result |
If result not understood contact physician liaison at laboratory |
|
| Communication of results |
Timely action after report received because diseases can progress rapidly |
|
| Patient advocate and educator |
If appropriate, enquire about patient's willingness to participate in research |
|
| Seek informed consent |
||
| Patient |
Accurate historian |
Possess and protect record of current medical history and record important symptoms |
| Participation |
Consider participation in research studies |
|
| Review and provide signed informed consent |
||
| Allow serum to be used for research |
||
| Regulatory bodies |
Quality assurance |
Attention to quality of samples provided for ongoing quality assurance programs |
| Utilize international standards and reference sera |
||
| Health care underwriters |
Budgeting |
Ensure that budget keeps pace with appropriate advances in serology |
| Support the use of tests that have been proven to have an impact on patient care and
outcome |
||
| Alignment of services |
Ensure that laboratory services are optimized |
|
| Consider impacts of laboratory consolidation on quality of care |
||
|
|
||
|
Fritzler et al. Arthritis Res Ther 2003 5:192 doi:10.1186/ar782 |
||